ArticleJOR spine2026
Inhibition of PLA2G15 Alleviates Palmitic Acid-Induced Lysosomal Membrane Permeabilization in Human Nucleus Pulposus Cells During Intervertebral Disc Degeneration.
Article in JOR spine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Intervertebral disc degeneration (IDD) imposes substantial economic and healthcare burdens, yet its mechanisms remain incompletely understood and effective pharmacological treatments are lacking. This study aimed to elucidate key factors driving IDD progression, specifically investigating lysosomal dysfunction and lysosomal membrane permeability (LMP) in human nucleus pulposus (NP) cells, and to identify potential therapeutic targets. Methods: We employed an integrative multiomics approach (transcriptomics, proteomics, metabonomics, and lipomics) combined with functional validation. Luciferase reporter assays investigated transcriptional regulation. The role of PLA2G15 in palmitic acid (PA)-induced lysosomal dysfunction was assessed in vitro and in vivo. Results: Integrated analysis identified lysosomal dysfunction and increased LMP as the key molecular features in human NP cells during IDD. PLA2G15 expression was significantly upregulated under PA overload conditions. PLA2G15-mediated PA-induced alterations in lysosomal membrane lipid composition and subsequent LMP by hydrolyzing lysosomal membrane phospholipids. The transcription factor C/EBPα directly bound the PLA2G15 promoter, regulating its transcription under PA overload conditions. Crucially, in vivo inhibition of PLA2G15 mitigated PA-induced LMP by restoring normal lysosomal membrane lipid composition, thereby attenuating IDD progression. Conclusions: This study demonstrates that PLA2G15 inhibition mitigates PA-induced IDD progression by preventing lysosomal dysfunction and LMP. Our findings reveal the significance of lysosomal membrane lipid composition alterations in human NP cells and identify PLA2G15 as a potential therapeutic target for IDD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.